According to Western Journal, Chinese neurotechnology company Neuracle has implanted its coin-sized Neural Electronic Opportunity, or NEO, device into the brain of a man who lost the use of his hand a decade ago following a spinal cord injury. As reported by the South China Morning Post, the brain-computer interface enabled the patient to control a robotic glove purely through thought, marking a milestone that puts Neuracle ahead of Elon Musk’s Neuralink in the race to bring such devices to market.
Doctors at Huashan Hospital in Shanghai carried out the procedure, placing the NEO on the surface of the patient’s brain. The man is now in recovery, and the device was able to capture his “stable, high-quality” brain signals during surgery, according to the South China Morning Post.
KIMBERLY GUILFOYLE’S AMBASSADORSHIP HAS ENDED BUT THE QUESTIONS HAVE NOT
July 22, 2026
Neuracle’s commercial clearance means it can sell its brain chip in China even as Western firms remain bound by more stringent regulatory and ethical safeguards. Neuralink, by contrast, must complete extensive clinical trials before its device can be sold in the United States, reflecting a system that prioritizes patient safety and long-term oversight over rapid deployment.
THE SUPREME COURT WILL DECIDE IF A NIGERIAN TERROR GROUP’S COOK GETS ASYLUM
Neuralink, Neuracle, the Embassy of China, and rival brain-interface firm Synchron “each did not immediately respond to the Daily Caller News Foundation’s request for comment.” That silence leaves key questions unanswered about how these companies intend to protect patient autonomy, data privacy, and informed consent as the technology advances.
TALARICO HOPES A NEW PAXTON STORY WILL BURY HIS 13-DAY DISAPPEARANCE
After surgical implantation on the brain’s surface, Neuracle’s NEO records the electrical activity of neurons as the patient imagines moving his hand, Gizmodo reported. A connected computer then translates those signals into commands that move the robotic glove, effectively bypassing the damaged spinal cord.
EL-SAYED'S CAMPAIGN IS NOW RESPONDING TO HIS SISTER’S POSTS —BRACE FOR IT!
Tech investor Aric Chang, founder and managing partner of PrototypeVC, argued on X that “\[w\]hile Neuralink still leads in tech, China is playing a game of deployment, becoming the first to market with a passable product and iterating in the field after collecting IRL data, the same playbook with EVs and humanoid robots.” His assessment highlights a familiar pattern in which Chinese firms rush products into real-world use, while American companies are constrained—some would say protected—by higher regulatory bars and stronger liability concerns.
ELIZABETH WARREN IS BACK TO REVIVE ‘ELECTION INTERFERENCE’ CLAIMS WEEKS BEFORE VOTE
Chang also maintained that China’s Neuracle is not truly “beating” Neuralink on the technological front. He noted that Neuracle’s system uses just eight electrodes resting on the brain’s surface, whereas Neuralink threads more than 1,000 electrodes directly into brain tissue, a far more complex and potentially more capable approach.
SIX FLAGS SHUTS DOWN CALIFORNIA GOLIATH AFTER MAN IS THROWN FROM TWIN COASTER IN GEORGIA
Neuralink’s “Precise Robotically IMplanted Brain-Computer InterfacE” (PRIME) trial is the first in-human study designed to evaluate the safety of its implant, according to an overview in the National Library of Medicine. Musk announced on X that the first human subject in this study received an implant in January 2024, a step that keeps the U.S. effort on a more cautious but technologically ambitious path.
SHUT DOWN SANCTUARY POLICIES ACT ADVANCES AFTER DEADLY CASES—AND PUTS BLUE STATES ON NOTICE
Eligibility for the Neuralink trial is tightly controlled, with criteria including “Life expectancy ? 12 months” and “presence of a stable caregiver,” according to the study documentation. The PRIME trial is expected to run until 2031, underscoring the long-term, methodical approach demanded by U.S. regulators before such devices can be widely marketed.
KIMBERLY GUILFOYLE CONFIRMS EXIT AS U.S. AMBASSADOR TO GREECE AFTER WHITE HOUSE RESIGNATION REQUEST
Synchron, another brain-computer interface company, secured the first FDA Investigational Device Exemption for a permanently implanted BCI in 2021. The firm reported “positive results” in 2024 after six participants used its device for 12 months, according to a Business Wire press release, further demonstrating that American innovation in this field remains robust despite regulatory hurdles.
BILL MAHER SAYS HE FEELS FREER TALKING TO TRUMP THAN OBAMA OR CLINTON—AND BLAMES DEMOCRATS FOR IT
Big Tech is also pushing into non-invasive brain decoding, with Meta announcing Brain2Qwerty v2 in June. A Meta blog post described it as “\[Brain2Qwerty v2 is\] the highest-performing end-to-end pipeline capable of real-time sentence decoding from non-invasive brain recordings, approaching levels of accuracy previously exclusive to techniques that require brain surgery,” a development that could offer less risky alternatives to surgical implants.
THE MONOLOGUE GILLIS DELIVERED ON SNL HAS WOKE CELEBRITIES FURIOUS
As China races ahead with commercial deployment of brain chips, conservatives will see a familiar trade-off: authoritarian efficiency versus the rule-of-law protections that slow American firms but safeguard human dignity and individual rights. The contrast between Neuracle’s rapid approval and the deliberate pace of Neuralink and Synchron underscores why many in the West remain wary of ceding technological leadership—and the ethical standards that come with it—to a regime that has repeatedly shown its willingness to treat citizens as test subjects in the name of progress.
